Article Sidebar
Views pdf: 24
PRELIMINARY ASSESSMENT OF THE VALUE OF POLYGENIC RISK SCORE FOR CORONARY ARTERY DISEASE AT THONG NHAT HOSPITAL
Main Article Content
Abstract
Background: In addition to traditional risk scores, polygenic risk scores (PRS) have recently been recommended for assessing the risk of coronary artery disease (CAD). However, data regarding the application of these scores in the Vietnamese population remain unavailable. Therefore, we conducted this study to provide preliminary insights into the predictive value of PRS for CAD in Vietnamese individuals. Methods: This observational study involved Vietnamese patients who underwent invasive coronary artery evaluation and PRS analysis for CAD at Thong Nhat Hospital. The CAD risk was categorized into three levels: moderate, moderate–high, and high. Results: From April 2023 to April 2025, a total of 30 patients were enrolled (mean age: 63 ± 17.5 years; range: 30–104 years). Based on the PRS, 73.4% (n=22) of patients were classified as moderate risk, 13.3% (n=4) as moderate–high risk, and 13.3% (n=4) as high risk. All patients in the moderate–high and high-risk groups had three-vessel coronary artery disease. Among the moderate-risk group, 12 out of 22 patients were diagnosed with CAD, and all these 12 patients had additional risk factors for CAD. Conclusions: Preliminary findings suggest that the PRS may have potential value in predicting CAD risk in the Vietnamese population. Further studies with larger sample sizes are warranted to validate these findings in Vietnam.
Article Details
Keywords
polygenic risk score, coronary artery disease, Vietnamese population
References
2. Aragam KG, Dobbyn A, Judy R, Chaffin M, Chaudhary K, Hindy G, Cagan A, Finneran P, Weng LC, Loos RJF et al: Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol 2020, 75(22):2769-2780.
3. Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, Roselli C, Kamatani Y, Komuro I, Aragam KG et al: Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol 2023, 8(2):130-137.
4. Damask A, Steg PG, Schwartz GG, Szarek M, Hagstrom E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN et al: Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation 2020, 141(8):624-636.
5. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA et al: 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024, 45(36):3415-3537.
6. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O'Donnell CJ, Willer CJ, Natarajan P, American Heart Association Council on G et al: Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2022, 146(8):e93-e118.
7. Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E, Sanderson SC, Kaski JP, McEvoy JW, Vardas P et al: Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease. Eur Heart J 2025, 46(15):1372-1383.
8. Aragam KG, Natarajan P: Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. Circ Res 2020, 126(9):1159-1177.